LEHI — Civica Rx, a nonprofit drug manufacturing company created by Intermountain Healthcare and others, has introduced the first two medicine it’s going to manufacture to offset the continued shortages affecting hospitals throughout the country.
Utah’s Civica Rx, with Denmark-based mostly Xellia Prescription drugs, will manufacture important and commonly used antibiotics, including vancomycin and daptomycin, each injectables used to treat infections. Shortages of those, and more, are impacting patient care.
The Lehi-based mostly firm, established in 2018, has stated it’s going to work with numerous suppliers to deliver 14 essential generic drugs this yr to greater than 900 hospitals.
“We thank Xellia for helping to paved the way in efforts to scale back persistent generic drug shortages in the USA, including remedies for critical infections brought on by micro organism which are immune to different antibiotics,” stated Martin VanTrieste, Civica president and CEO.
He stated that by serving to to stabilize the availability of vancomycin and daptomycin, “we could have a direct impression on affected person safety and public well being by providing consistent access to antibiotics which are necessary remedy options in the administration of inauspicious-to-deal with and life-threatening infections.”
Xellia will make drugs for Civica Rx beneath its Abbreviated New Drug Software and Civica shall be chargeable for proper labeling and shelling out, utilizing the U.S. New Drug Code policy.